Hydrogel Drug Delivery Matrix for Stable Reservoir Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hydrogel-based drug delivery systems face issues such as residual material from cross-linking agents, low drug concentration, instability of drug carriers like liposomes, and unpredictable release rates, as well as migration and aggregation of drug reservoirs after injection.
Innovation Solution
A hydrogel binding matrix that encapsulates drug reservoirs before cross-linking, using gentle cross-linking conditions to maintain stability and even distribution, allowing controlled release of drugs at targeted sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If free-radical generating compounds or radiation are used to cross-link hydrogels, then the hydrogel structure is formed, but residual material remains that is potentially dangerous to the receiving subject
Solution Approach 1:
The patent removes harmful free-radical generating compounds and radiation sources from the cross-linking process. Instead, it uses non-toxic cross-linking agents that do not leave residual harmful material, thereby extracting the harmful element while maintaining the hydrogel structure formation capability.
Solution Approach 2:
The patent introduces an intermediary substance - a non-toxic cross-linking agent - that mediates the cross-linking process without leaving harmful residues. This intermediary enables the hydrogel structure formation while avoiding the toxicity issue associated with free-radical methods.
2Ease of manufacture
If passive diffusion is used to load drugs into hydrogels, then the loading process is simple, but the resulting drug concentration is low
Solution Approach 1:
The patent applies preliminary action by pre-loading drugs into reservoirs or particles before incorporating them into the hydrogel matrix. This allows high drug concentrations to be achieved in the reservoirs themselves, which are then distributed within the hydrogel, maintaining both ease of manufacture and high drug concentration.
3Quantity of substance
If thermal treatment or irradiation is used to load drugs into hydrogels, then higher drug concentrations can be achieved, but the heat or radiation causes drugs to react with the hydrogel or become inactivated
Solution Approach 1:
The patent extracts thermal treatment and irradiation methods from the drug loading process. Instead, it uses non-thermal, non-radiative methods such as physical entrapment during hydrogel formation or incorporation into reservoirs, thereby achieving high drug concentrations without compromising drug stability through heat or radiation exposure.
4Ease of operation
If liposome formulations are used as drug delivery vehicles, then they can deliver drugs to targeted sites, but they easily extrude back out through interstitial spaces or drain away
Solution Approach 1:
The patent uses nested doll by encapsulating liposome formulations within the hydrogel matrix structure. The liposomes are nested inside the hydrogel network, which provides physical containment preventing extrusion through interstitial spaces, while the liposomes retain their drug delivery functionality.
Solution Approach 2:
The patent creates a composite material system combining liposomes with hydrogel. The hydrogel provides structural stability and prevents drainage, while the liposomes provide targeted drug delivery capability, achieving both stability and delivery function in a composite formulation.
5Stability of the object's composition
If liposome formulations are made sufficiently dilute to remain stable, then they maintain stability, but they prevent the target molecule from being delivered to the target tissue in a timely fashion
Solution Approach 1:
The patent applies local quality by creating different concentrations in different locations: dilute liposome formulations are used throughout most of the hydrogel matrix to maintain stability, while concentrated drug reservoirs or particles are localized at specific sites to ensure timely delivery. This spatial variation in concentration resolves the contradiction between stability and delivery speed.
6Quantity of substance
If dense hydrogel particles or porous particles are used as drug reservoirs, then they can hold drugs, but they migrate after injection or placement and aggregate in one spot
Solution Approach 1:
The patent merges drug reservoirs or particles with the hydrogel matrix through physical entrapment during hydrogel formation. The particles are incorporated into the hydrogel network structure, which prevents migration and aggregation while maintaining the particles' drug loading capacity. The hydrogel acts as a binding matrix that holds particles in place.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ensures predictable and reproducible drug delivery with high concentrations, preventing drug degradation and migration, and enabling varied release rates based on hydrogel composition and density.
Implementation Method 1
As the hydrogel binding matrix solidifies into a gel state, it creates cross-links that do not disrupt or react with the one or more target molecules contained within the drug reservoirs
Implementation Method 2
The hydrogel binding matrix does not significantly hinder diffusion and elution of the active target molecule from the drug reservoir
Data Source
AI summary
A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.